Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358315 · ClinicalTrials.gov registry record
Consumer Assessment of Tobacco Flavor and Odor
A clinical trial, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- 29
- Enrollment target
NCT04358315: Clinical Trial study, sponsored by Roswell Park Cancer Institute.
NCT04358315 is a clinical trial that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04358315 was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This trial studies consumer assessments of tobacco flavor and odor. This study will compare the ability of expert and consumer panels to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures.
Primary Outcome
Subjects will be asked to identify various concentrations of flavored e-liquids
Interventions
- OTHER Questionnaire Administration
- BEHAVIORAL Behavioral Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2025-12-09 |
Why NCT04358315 stopped before completion
NCT04358315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT04358315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04358315 about?
NCT04358315 is a clinical study titled "Consumer Assessment of Tobacco Flavor and Odor". This trial studies consumer assessments of tobacco flavor and odor. This study will compare the ability of expert and consumer panels to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures.
What is the current status of trial NCT04358315?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2023-04-03. Estimated completion is 2025-12-09.
What interventions are being tested in trial NCT04358315?
The interventions under investigation include: Questionnaire Administration (OTHER), Behavioral Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04358315?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI